Coriell researchers find new genetic indicator of obesity risk

Coriell researchers find new genetic indicator of obesity risk

Glucose-lowering drug reduces obesity indices in children and adolescents, study shows Coriell researchers analyzed 5,251 samples from the Coriell Personalized Medicine Collaborative (CPMC). The CPMC is a decade-long personalized medicine study in which thousands of participants submitted their DNA, and extensive family, medical and lifestyle histories for analysis. The group analyzed for this study included more than 2,000 members of the United States Air Force and their family members. In the genome-wide association study (GWAS), the research team at Coriell identified the locus rs11670527, located downstream to the ZNF264 gene on chromosome 19, as having a significant association with elevated body mass index (or BMI). The study notes that this gene, ZNF264 , is also near another genetic variant, rs2361128, which was identified in the Framingham Heart Study as being associated with BMI, adding to evidence that ZNF264 has a role in influencing BMI. ZNF264 is known to encode a zinc-finger protein found in the nucleus. Unlike in the Framingham study, however, the rs2361128 SNP did not replicate with genome-wide significance in this study. Source: Coriell Institute for Medical Research Journal reference: Kusic, D.M., et al. (2020) rs11670527 Upstream of ZNF264 Associated with Body Mass Index in the Coriell Personalized Medicine Collaborative. Military Medicine . doi.org/10.1093/milmed/usz216 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More